Advertisement

Critical role of epidermal growth factor receptor in neutropenic fever

 

"Research Article"

American Journal of BioMedicine  Volume 3, Issue 2, pages 75-87, February 2015


Debolina Bokemeyer; Ratna Price; Sarita Saltz; Min Engelman; Johanna Loehrer

Abstract

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The identification of EGFR as an oncogene has led to the development of anticancer therapeutics directed against EGFR. The most common adverse effect of EGFR inhibitors, found in more than 90% of patients, is a papulopustular rash and in 10% to 15% of patients the effects can be serious and require treatment. While the risk of neutropenic fever toxicity has only recently been recognized. A total of 279 patients were enrolled in the present study. Progression-free survival (PFS) and overall survival (OS) of patients with a lowh grade of neutropnic fever were significantly longer than those with a high grade of neutropnic fever (median PFS: 3.6 months vs 8.4 months, P<0.001; median OS: 7.6 months vs 17.1 months, P=0.006, respectively).

Keywords: Cancer; Neutropenic fever; EGFR; ErbB-1


Limited Access             Full Text-PDF                Feedback


References

1.  Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015; 13:37. [Abstract/Full-Text]

2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341–354. [PubMed]

3. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593–1611. [PubMed]

4. Li KJ, Siao SC, Wu CH. et al. EGF receptor-dependent mechanism may be involved in the Tamm–Horsfall glycoprotein-enhanced PMN phagocytosis via activating Rho family and MAPK signaling pathway. Molecules 2013;19:1328–1343. [Scopus]

5. Vinante F, Rigo A. Heparin-binding EGFR/diphtheria toxin receptor in normal and neoplastic hematopoiesis. Toxins 2013;5:1180–1201. [Scopus]

6. Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012;67:400–408. [PubMed] [Scopus]

7. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S.  Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 2012;11:S9–19. [PubMed] [Scopus]

8. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23:1672–1679. [PubMed] [Scopus]

9. Funakoshi T, Suzuki M,Tamur K. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. Cancer treatment reviews 2014; 40(0):1221–1229. [Abstract/Full-Text]

10. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013; 35:1282-1303. [PubMed]

11. Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the EGFR in cancer: apoptosis takes center stage. Cancer Res 2003; 63:1-5. [PubMed]

12. Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with cetuximab–an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009; 77:124-133. [PubMed]

13. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.J Chemother. in press.

14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol 2011;12: 104–117. [PubMed] [Scopus]

15. Ding L, Getz G, Wheeler DA. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537–540. [PubMed]

16. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012;2: 934–947. [CrossRef] [PubMed]

17. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of EGFR mutations in human glioblastomas. Cancer Res 2000; 60: 1383–1387. [PubMed]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: